Analysts expect that Eyenovia Inc (NASDAQ:EYEN) will report earnings of ($0.45) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Eyenovia’s earnings. The firm is scheduled to announce its next earnings results on Tuesday, November 13th.
On average, analysts expect that Eyenovia will report full-year earnings of ($1.73) per share for the current financial year, with EPS estimates ranging from ($1.78) to ($1.68). For the next fiscal year, analysts forecast that the business will report earnings of ($1.61) per share, with EPS estimates ranging from ($1.80) to ($1.42). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Eyenovia.
Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.09.
Separately, Zacks Investment Research upgraded Eyenovia from a “sell” rating to a “hold” rating in a report on Wednesday, July 25th.
Hedge funds have recently bought and sold shares of the company. Fairpointe Capital LLC bought a new position in shares of Eyenovia in the second quarter valued at approximately $313,000. Sabby Management LLC bought a new position in shares of Eyenovia in the first quarter valued at approximately $908,000. Highbridge Capital Management LLC bought a new position in shares of Eyenovia in the first quarter valued at approximately $1,373,000. Millennium Management LLC bought a new position in shares of Eyenovia in the first quarter valued at approximately $2,525,000. Finally, Uniplan Investment Counsel Inc. bought a new position in shares of Eyenovia in the first quarter valued at approximately $3,248,000. Institutional investors own 12.28% of the company’s stock.
NASDAQ:EYEN opened at $3.90 on Friday. The stock has a market cap of $40.19 million and a PE ratio of -1.78. Eyenovia has a fifty-two week low of $2.94 and a fifty-two week high of $10.74.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Featured Story: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.